Other European Operations
Otsuka Map
Otsuka Pharmaceutical Europe Ltd. (OPEL) has established businesses in many European markets, shown on the map above. In our other European countries*, Otsuka’s European operation supplies its medicines through a combination of collaborations and distributors. Other Otsuka Pharmaceutical entities in Europe include:
  • Otsuka Europe Development and Commercialisation Ltd. (OEDC) – focused on clinical strategy, regulatory affairs, pharmacovigilance, global quality management and data and document management. Based in Frankfurt and London
  • Otsuka Novel Products GmbH in Munich, Germany (Marketing Authorisation Holder) is working on commercial and public health strategies to improve TB care and ensure rational use of new anti-TB medications.
  • Astex Therapeutics Ltd. – focused on the discovery of novel drugs, particularly in the oncology and CNS therapeutic areas. Based in Cambridge, UK
  • Interpharma Praha, a.s. (IPP) – offer a broad range of research, development and contract manufacturing services focused on the areas of X-ray contrast media, active pharmaceutical ingredients and drug products, and nutraceuticals. Based in Prague, Czech Republic
  • Taiho Pharma Europe Ltd. – engaged in research and development programmes and regulatory support for obtaining EU Marketing Authorisation of oncology drugs. Taiho is part of the Otsuka family of companies but operates independently from Otsuka Pharmaceutical Co., Ltd. Based in Uxbridge, UK
*Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia and Slovenia.

Date of preparation: January 2019

Reference OPEL/0119/COMS/1000d

Otsuka's Global TB Programme


最新1本道dvd更新 1本道Av在線Otsuka Pharmaceutical Company’s (OPC) global tuberculosis programme exemplifies the company’s creative ingenuity and patient-centred approach. We have worked relentlessly for more than 40 years to find a treatment option for patients suffering from multidrug-resistant tuberculosis (MDR-TB). Remaining focused on this dream, European regulatory approval for a novel compound was granted in April 2014.